A Phase I/Ib Study to Investigate PMD-026 in Women with Triple-Negative Breast Cancer
Phase of Trial: Phase I
Latest Information Update: 27 Dec 2018
At a glance
- Drugs PMD 026 (Primary)
- Indications Breast cancer
- Focus Adverse reactions
- Sponsors Phoenix Molecular Designs
- 27 Dec 2018 According to a Phoenix Molecular Designs media release, this trial is scheduled to initiate in mid- 2019.
- 22 Sep 2018 New trial record
- 18 Sep 2018 According to a Phoenix Molecular Designs media release, the company raises 2.7 dollar M to develop PMD-026 for triple-negative breast cancer.The proceeds from the completed financing and the non-dilutive capital from recent research grants will advance PMD-026 through critical IND-enabling studies and will begin planning around this upcoming study, which the company is excited to initiate.